Free tool
FAERS Monitor: Zavzpret
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216386 or its brand name (Zavzpret, Zavegepant Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
892
Serious
83
9% of reports
Hospitalization
24
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dysgeusia259
- drug ineffective147
- nasal discomfort85
- nausea81
- throat irritation75
- vomiting71
- migraine45
- therapeutic product effect incomplete44
- headache38
- off label use36
- taste disorder36
- burning sensation31
- dizziness22
- oropharyngeal pain20
- fatigue19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 236 |
| 2024 | 266 |
| 2025 | 248 |
| 2026 | 142 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,267 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nasal discomfortSignal | 85 | 255.5 | 208.5 | 21,077 |
| dysgeusiaSignal | 259 | 82.5 | 74.4 | 20,769 |
| taste disorderSignal | 36 | 41.9 | 30.4 | 1,396 |
| throat irritationSignal | 75 | 39.5 | 31.8 | 2,776 |
| therapeutic product effect incompleteSignal | 44 | 14.6 | 10.9 | 545 |
| migraineSignal | 45 | 11.1 | 8.4 | 406 |
| burning sensationSignal | 31 | 10.4 | 7.4 | 256 |
| oropharyngeal painSignal | 20 | 5.1 | 3.3 | 62 |
| vomitingSignal | 71 | 3.6 | 2.8 | 131 |
| drug ineffectiveSignal | 147 | 2.6 | 2.3 | 157 |
| nauseaSignal | 81 | 2.4 | 2.0 | 68 |
| headache | 38 | 1.4 | 1.0 | 5 |
| dizziness | 22 | 1.0 | 0.7 | 0 |
| off label use | 36 | 1.0 | 0.7 | 0 |
| fatigue | 19 | 0.6 | 0.4 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.